{"id":"W4407007830","doi":"10.1182/bloodadvances.2024013656","title":"Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel","year":2025,"lang":"en","type":"review","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Odds ratio; Internal medicine; Refractory (planetary science); Leukapheresis; Surgery; Gastroenterology; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001805501,0.0005943749,0.002681824,0.0007974622,0.00003107122,0.00001818713,0.0003162597,0.0001887127,0.000793188],"category_scores_gemma":[0.00009265808,0.0003447625,0.0003363493,0.001832648,0.0001162275,0.00009516531,0.00007890152,0.0004530563,0.00004431739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002217224,"about_ca_system_score_gemma":0.001004117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009095041,"about_ca_topic_score_gemma":0.00003409196,"domain_scores_codex":[0.9973091,0.0001571729,0.0006152774,0.0006614036,0.000716386,0.0005406514],"domain_scores_gemma":[0.9982088,0.0002279533,0.0002862345,0.0007826344,0.0002526281,0.0002417546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001624417,0.00191123,0.02409142,0.01222093,0.001391023,0.0001192217,0.00004130519,0.00001293332,0.00005131699,0.000001203634,0.0001019823,0.958433],"study_design_scores_gemma":[0.0205755,0.02772737,0.02533253,0.1298608,0.004777452,0.00005956404,0.00001813228,0.000003177297,0.0004390912,0.000006236774,0.7896399,0.001560238],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02727146,0.964308,0.000002806168,0.00001096631,0.00002137678,0.003185251,0.0002334361,0.00005036195,0.004916349],"genre_scores_gemma":[0.0005085494,0.982369,0.000389452,0.00001775003,0.00007237105,0.0001982301,0.0004477922,0.0001076361,0.01588921],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9568728,"threshold_uncertainty_score":0.9999005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01537286737108856,"score_gpt":0.3482179956828738,"score_spread":0.3328451283117853,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}